Moguisteine, a new antitussive drug, has no effect on steady-state theophylline pharmacokinetics in patients with chronic obstructive pulmonary disease

E. E. Guffanti, P. Scarpazza, D. Colombo, S. Canali, D. Ratti, G. Scarpazza, E. Marchi

Research output: Contribution to journalArticle

Abstract

The effect of the oral antitussive moguisteine (200 mg three times daily for 5 to 6 days) on the pharmacokinetics of theophylline was studied in 12 hospitalized men with chronic obstructive pulmonary disease (COPD). Five patients received oral theophylline 350 mg twice daily (group A), and 7 patients received intravenous aminophylline 240 mg twice daily (group B). Serum theophylline concentration-time curves were compared before and on the last day of moguisteine treatment. Neither the time-course profiles nor the pharmacokinetic theophylline parameters in either group demonstrated any clinically significant changes as a result of moguisteine administration. Moguisteine was well tolerated, as shown by evaluation of vital signs and clinical laboratory tests. No adverse events occurred. Moguisteine may be safely administered to patients with COPD who are receiving theophyllinic agents.

Original languageEnglish
Pages (from-to)185-196
Number of pages12
JournalAdvances in Therapy
Volume12
Issue number3
Publication statusPublished - 1995

Fingerprint

Antitussive Agents
Theophylline
Chronic Obstructive Pulmonary Disease
Pharmacokinetics
Aminophylline
Vital Signs
moguisteine
Serum

Keywords

  • chronic obstructive pulmonary disease
  • moguisteine
  • pharmacokinetics
  • theophylline

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Moguisteine, a new antitussive drug, has no effect on steady-state theophylline pharmacokinetics in patients with chronic obstructive pulmonary disease. / Guffanti, E. E.; Scarpazza, P.; Colombo, D.; Canali, S.; Ratti, D.; Scarpazza, G.; Marchi, E.

In: Advances in Therapy, Vol. 12, No. 3, 1995, p. 185-196.

Research output: Contribution to journalArticle

Guffanti, E. E. ; Scarpazza, P. ; Colombo, D. ; Canali, S. ; Ratti, D. ; Scarpazza, G. ; Marchi, E. / Moguisteine, a new antitussive drug, has no effect on steady-state theophylline pharmacokinetics in patients with chronic obstructive pulmonary disease. In: Advances in Therapy. 1995 ; Vol. 12, No. 3. pp. 185-196.
@article{1171973de0f046fd86245398ea73e289,
title = "Moguisteine, a new antitussive drug, has no effect on steady-state theophylline pharmacokinetics in patients with chronic obstructive pulmonary disease",
abstract = "The effect of the oral antitussive moguisteine (200 mg three times daily for 5 to 6 days) on the pharmacokinetics of theophylline was studied in 12 hospitalized men with chronic obstructive pulmonary disease (COPD). Five patients received oral theophylline 350 mg twice daily (group A), and 7 patients received intravenous aminophylline 240 mg twice daily (group B). Serum theophylline concentration-time curves were compared before and on the last day of moguisteine treatment. Neither the time-course profiles nor the pharmacokinetic theophylline parameters in either group demonstrated any clinically significant changes as a result of moguisteine administration. Moguisteine was well tolerated, as shown by evaluation of vital signs and clinical laboratory tests. No adverse events occurred. Moguisteine may be safely administered to patients with COPD who are receiving theophyllinic agents.",
keywords = "chronic obstructive pulmonary disease, moguisteine, pharmacokinetics, theophylline",
author = "Guffanti, {E. E.} and P. Scarpazza and D. Colombo and S. Canali and D. Ratti and G. Scarpazza and E. Marchi",
year = "1995",
language = "English",
volume = "12",
pages = "185--196",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer Healthcare",
number = "3",

}

TY - JOUR

T1 - Moguisteine, a new antitussive drug, has no effect on steady-state theophylline pharmacokinetics in patients with chronic obstructive pulmonary disease

AU - Guffanti, E. E.

AU - Scarpazza, P.

AU - Colombo, D.

AU - Canali, S.

AU - Ratti, D.

AU - Scarpazza, G.

AU - Marchi, E.

PY - 1995

Y1 - 1995

N2 - The effect of the oral antitussive moguisteine (200 mg three times daily for 5 to 6 days) on the pharmacokinetics of theophylline was studied in 12 hospitalized men with chronic obstructive pulmonary disease (COPD). Five patients received oral theophylline 350 mg twice daily (group A), and 7 patients received intravenous aminophylline 240 mg twice daily (group B). Serum theophylline concentration-time curves were compared before and on the last day of moguisteine treatment. Neither the time-course profiles nor the pharmacokinetic theophylline parameters in either group demonstrated any clinically significant changes as a result of moguisteine administration. Moguisteine was well tolerated, as shown by evaluation of vital signs and clinical laboratory tests. No adverse events occurred. Moguisteine may be safely administered to patients with COPD who are receiving theophyllinic agents.

AB - The effect of the oral antitussive moguisteine (200 mg three times daily for 5 to 6 days) on the pharmacokinetics of theophylline was studied in 12 hospitalized men with chronic obstructive pulmonary disease (COPD). Five patients received oral theophylline 350 mg twice daily (group A), and 7 patients received intravenous aminophylline 240 mg twice daily (group B). Serum theophylline concentration-time curves were compared before and on the last day of moguisteine treatment. Neither the time-course profiles nor the pharmacokinetic theophylline parameters in either group demonstrated any clinically significant changes as a result of moguisteine administration. Moguisteine was well tolerated, as shown by evaluation of vital signs and clinical laboratory tests. No adverse events occurred. Moguisteine may be safely administered to patients with COPD who are receiving theophyllinic agents.

KW - chronic obstructive pulmonary disease

KW - moguisteine

KW - pharmacokinetics

KW - theophylline

UR - http://www.scopus.com/inward/record.url?scp=0029063928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029063928&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029063928

VL - 12

SP - 185

EP - 196

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 3

ER -